Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents

European Journal of Medicinal Chemistry

Volumn 69, Issue , 2013, Pages 527-536

  Gopinath, Vadiraj S ^a   Pinjari, Jakir ^a   Dere, Ravindra T ^a   Verma, Aditya ^b   Vishwakarma, Preeti ^b   Shivahare, Rahul ^b   Moger, Manjunath ^a   Kumar Goud, Palusa Sanath ^a   Ramanathan, Vikram ^a   Bose, Prosenjit ^a   Rao, M V S ^a   Gupta, Suman ^b   Puri, Sunil K ^b   Launay, Delphine ^c   Martin, Denis ^c  

^a Advinus Therapeutics Private Limited Bangalore   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

2 Substituted quinolines; Antileishmanial activity; Liver microsomes; Luciferase assay; Metabolic stability

Indexed keywords

ANTILEISHMANIAL AGENT; CHLORIDE; HALOGEN; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; NONHUMAN;

2-SUBSTITUTED QUINOLINES; ANTILEISHMANIAL ACTIVITY; LIVER MICROSOMES; LUCIFERASE ASSAY; METABOLIC STABILITY;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG DESIGN; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; MICE; PARASITIC SENSITIVITY TESTS; QUINOLINES;

EID: 84884689090     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.08.028     Document Type: Article

References (31)

1. L. Rogers Note on the occurrence of Leishman-Donovan bodies in "cachexial fevers" including Kala-azar Br. Med. J. 1 1904 1249 1251
2. P. Desjeux The increase of risk factors for leishmaniasis worldwide Trans. R. Soc. Trop. Med. Hyg. 95 2001 239 243 (Pubitemid 33713068)
3. R.D. Pearson, and A. de Queiroz Sousa Clinical spectrum of leishmaniasis Clin. Infect. Dis. 22 1996 1 11
4. P. Trouiller, and P. Olliaro Drug development output from 1975 to 1996 what proportion for tropical diseases? Int. J. Infect. Dis. 3 1999 61 63
5. S. Kumari, and V.J. Ram Visceral leishmaniasis: clinical features, pathology, diagnosis and chemotherapeutic developments Drug News Prospect. 15 2002 417 431 (Pubitemid 35339864)
6. M. Reddy, S.S. Gill, S.R. Kalkar, W. Wu, P.J. Anderson, and P.A. Rochon Oral drug therapy for multiple neglected tropical diseases: a systematic review JAMA 298 2007 1911 1924 (Pubitemid 350005235)
7. C.P. Thakur, R.K. Singh, S.M. Hassan, R. Kumar, S. Narain, and A. Kumar Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases Trans. R. Soc. Trop. Med. Hyg. 93 1999 319 323 (Pubitemid 29348832)
8. H. Sindermann, S.L. Croft, K.R. Engel, W. Bommer, H.J. Eibl, C. Unger, and J. Engel Miltefosine (Impavido): the first oral treatment against leishmaniasis Med. Microbiol. Immunol. 193 2004 173 180 (Pubitemid 40063681)
9. T.A. Patel, and D.N. Lockwood Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases Trop. Med. Int. Health 14 2009 1064 1070
10. S. Sundar, T.K. Jha, P.T. Chandreshwar, K.S. Prabhat, and S.K. Bhattacharya Injectable paromomycin for visceral leishmaniasis in India N. Engl. J. Med. 356 2007 2567 2569
11. R. Dietze, S.F. Carvalho, L.C. Valli, J. Berman, T. Brewer, W. Milhous, J. Sanchez, B. Schuster, and M. Grogl Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi Am. J. Trop. Med. Hyg. 65 2001 685 689 (Pubitemid 34049456)
12. B.C. Walton, J. Harper, and R.A. Neal Effectiveness of Allopurinol against Leishmania braziliensis panamensis in Aotus trivirgatus Am. J. Trop. Med. Hyg. 32 1983 46 50 (Pubitemid 13186837)
13. R.A. Bumb, and R.D. Mehta Oral rifampicin in cases of cutaneous leishmaniasis with multiple lesions (a pilot study) Indian J. Dermatol. Venereol. Leprol. 68 2002 272
14. H.W. Murray, and J. Hariprashad Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis Antimicrob. Agents Chemother. 40 1996 586 587 (Pubitemid 26071526)
15. H.L. Ziegler, H.S. Hansen, D. Staerk, S.B. Christensen, H. Hägerstrand, and J.W. Jaroszewski The antiparasitic compound licochalcone A is a potent echinocytogenic agent that modifies the erythrocyte membrane in the concentration range where antiplasmodial activity is observed Antimicrob. Agents Chemother. 48 2004 4067 4071 (Pubitemid 39304652)
16. S.L. Croft, R.A. Neal, E.A. Thornton, and D.B. Herrmann Antileishmanial activity of the ether phospholipid ilmofosine Trans. R. Soc. Trop. Med. Hyg. 87 1993 217 219
17. J.D. Berman, and J.V. Gallalee Antileishmanial activity of human red blood cells containing Formycin A J. Infect. Dis. 151 1985 698 703 (Pubitemid 15102168)
18. K.A. Werbovetz, A.K. Bhattacharjee, J.J. Brendle, and J.P. Scovill Analysis of stereoelectronic properties of camptothecin analogues in relation to biological activity Bioorg. Med. Chem. 8 2000 1741 1747 (Pubitemid 30427240)
19. A. Fournet, A.A. Barrios, V. Munoz, R. Hocquemiller, A. Cave, and J. Bruneton 2-substituted quinoline alkaloids as potential antileishmanial drugs Antimicrob. Agents Chemother. 37 1993 859 863 (Pubitemid 23096891)
20. M.A. Fakhfakh, A. Fournet, E. Prina, J.F. Mouscadet, X. Franck, R. Hocquemiller, and B. Figadère Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections Bioorg. Med. Chem. 11 2003 5013 5023 (Pubitemid 37352989)
21. C.R. Hauser, and G.A. Reynolds Reactions of β-keto esters with aromatic amines. Syntheses of 2- and 4-hydroxyquinoline derivatives J. Am. Chem. Soc. 70 1948 2402 2404
22. S. Gupta, S.C. Sharma, and V.M.L. Srivastava Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis Acta Trop. 94 2005 41 47 (Pubitemid 40445378)
23. M. Sharma, K. Chauhan, R. Shivahare, P. Vishwakarma, M. Suthar, A. Sharma, S. Gupta, J.K. Saxena, J. Lal, P. Chandra, B. Kumar, and P.M.S. Chauhan Discovery of a new class of natural product-inspired quinazolinone hybrid as potent antileishmanial agents J. Med. Chem. 56 2013 4374 4392
24. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63 (Pubitemid 14203433)
25. W. Huber, and J.C. Koella A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites Acta Trop. 55 1993 257 261
26. E. Beveridge Chemotherapy of leishmaniasis R.J. Schnitzer, F. Hawking, Experimental Chemotherapy 1963 Academic Press New York, London 257 280
27. S. Bhatnagar, P.Y. Guru, J.C. Katiyar, R. Srivastava, A. Mukherjee, M.S. Akhtar, M. Seth, and A.P. Bhaduri Exploration of antileishmanial activity in heterocycles; results of their in vivo & in vitro bioevaluations Indian J. Med. Res. 89 1989 439 444 (Pubitemid 20083506)
28. S. Gupta, S. Tiwari, A.P. Bhaduri, and G.K. Jain Anilino-(2-bromophenyl) acetonitrile: a promising orally effective antileishmanial agent Acta Trop. 84 2002 165 173 (Pubitemid 35346559)
29. M. Jemal, Z. Ouyang, and Y.Q. Xia Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography Biomed. Chromatogr. 24 2010 2 19
30. T. Singtoroj, J. Tarning, A. Annerberg, M. Ashton, Y. Bergqvist, N.J. White, N. Lindegardh, and N.P. Day A new approach to evaluate regression models during validation of bioanalytical assays J. Pharm. Biomed. Anal 41 2006 219 227
31. ® Version 4.1 User's guide, Chapter 9, Non-compartmental Analysis. Page 215-240, Pharsight Corporation, Mountain View, California 94040.